We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $581M
1-Year Est. Return 373.68%
This Fund
S&P 500
This Quarter Est. Return
+8.95%
1 Year Est. Return
+373.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$312M
AUM Growth
-$2.13M
Cap. Flow
-$12.8M
Cap. Flow %
-4.11%
Top 10 Hldgs %
50%
Holding
82
New
21
Increased
16
Reduced
15
Closed
29

Top Buys

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$9.15M
2
LEGN icon
Legend Biotech
LEGN
+$8.75M
3
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$8.75M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$8.52M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$8.52M

Top Sells

Rank Stock Value
1
ROIV icon
Roivant Sciences
ROIV
+$21.4M
2
RVMD icon
Revolution Medicines
RVMD
+$11.3M
3
NUVL
Nuvalent
NUVL
+$9.55M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$9.21M
5
CGON icon
CG Oncology
CGON
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.17%
2 Financials 0.51%
3 Miscellaneous 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLDB icon
76
Solid Biosciences
SLDB
$1.1B
– –
-198,150
Closed -$733K
SLNO
77
DELISTED
Soleno Therapeutics
SLNO
– –
-11,155
Closed -$797K
SWTX
78
DELISTED
SpringWorks Therapeutics
SWTX
– –
-159,305
Closed -$7.03M
SYRE icon
79
Spyre Therapeutics
SYRE
$7.85B
– –
-136,139
Closed -$2.2M
XENE icon
80
Xenon Pharmaceuticals
XENE
$5.79B
– –
-274,633
Closed -$9.21M
BCAX
81
Bicara Therapeutics
BCAX
$1.53B
– –
-47,078
Closed -$613K
SION
82
Sionna Therapeutics
SION
$325M
– –
-60,000
Closed -$628K
1 2 3
4

Similar funds

PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
Cambridge Advisors Omaha, Nebraska $582M AUM 19.14% 1-Year Est. Return

Stempoint Capital's Q2 2025 Portfolio in Review

As of Q2 2025, Stempoint Capital held 82 positions worth $312M, down 0.68% from $314M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Stempoint Capital withdrew a net $12.8M in Q2 2025, closing 29 positions and reducing 15 holdings. Its most notable exit was Revolution Medicines, an estimated $11.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Miscellaneous.

Against the trend, Stempoint Capital opened a new position in Mineralys Therapeutics worth $8.55M.

  • Stempoint Capital's largest Q2 2025 buy was Mineralys Therapeutics: 631,586 shares worth $8.55M.
  • Stempoint Capital added most to Rhythm Pharmaceuticals in Q2 2025, an estimated $8.75M increase.
  • Stempoint Capital's biggest Q2 2025 reduction was Roivant Sciences, cutting an estimated $21.4M.
  • Stempoint Capital fully exited Revolution Medicines in Q2 2025, selling an estimated $11.3M.
  • Stempoint Capital's ten largest holdings make up 50% of its $312M portfolio in Q2 2025.
  • Stempoint Capital opened 21 new positions and closed 29 in Q2 2025.
  • Stempoint Capital's portfolio value fell 0.68% quarter-over-quarter to $312M.

Based on Stempoint Capital's 13F filing for Q2 2025, filed 14 Aug 2025.